CBRE Group, Inc.
CBRECBRE Group, Inc.'s earnings have outrun its stock. EPS grew +22.6% in a year against a −15.6% price move.
The sharpest disagreement: annual EPS moved +22.6% against a −15.6% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (2 weeks in) while the P/E sits at the 48th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +4.2% year on year, and 112% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
CBRE Group, Inc. trades at $139, in a downtrend and 2 weeks into that stage. That is −5.5% against its own 200-day average. It sits at 29% of a 52-week range of $125 to $172. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks.
Today the stock is in a downtrend — week 2 of stage 4. At $139 it trades −5.5% versus its 200-day average and sits at 29% of its 52-week range ($125–$172).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +429% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
CBRE Group, Inc. trades at 32.0× P/E, mid-range by its own standards (48th percentile). Its long-run median P/E is 32.3×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 32.0× is mid-range by its own standards (48th percentile), against a long-run median of 32.3× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +22.6% against a −15.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +20.9%/yr price move, ~+18.2%/yr came from earnings growth and ~+2.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
CBRE Group, Inc. reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 10.9% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +13.4% | +9.6% | — | — |
| Profit | +23.1% | −3.4% | — | — |
| EPS | +22.6% | −3.5% | — | — |
| Stock price | −15.6% | +20.9% | +7.7% | +17.2% |
4-Factor Sector Score
58.3/100 — rank 3 of 27 in Real Estate Services · 85% evidence confidence
CBRE Group, Inc. scores 58.3 out of 100 against the 27 companies it is compared with in Real Estate Services, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.9 + 15.1 + 10.1 + 10.2 = 58.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
CBRE Group, Inc. reported $11.2 B of revenue in the Jun 26 quarter, +15.5% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 9.9% a year. The last full year, FY25, came in at $40.5 B. The last four reported quarters add to $43.7 B.
FY25 revenue came in at $40.5 B (+13.4% on the year), capping 4 years at 9.9% compound. The latest quarter (Jun 26) printed $11.2 B, +15.5% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +14.9% growth against the decade's 9.9% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +14.7% over the last 4 quarters against +14.8%/yr over the last 8 — stabilising; TTM profit +23.1% vs +21.2%/yr — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
CBRE Group, Inc.'s operating margin is 3.2% in the Jun 26 quarter, −0.6 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 3.5% to 5.9%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 3.2%, −0.6 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 3.5%–5.9%.
🚨 Why the margin moved: operating margin went −0.6 pp year on year while gross margin went +0.4 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
CBRE Group, Inc. earned $0.3 B of net profit in the Jun 26 quarter, +4.2% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $1.3 B. The 4-year compound rate is −8.7%. That is 2.2% of the quarter's revenue. The same quarter a year earlier earned $0.2 B.
Jun 26 profit was $0.3 B, +4.2% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $1.3 B (+23.1%), and the 4-year compound rate is −8.7%.
Why profit moved: revenue contributed +15.5% and the margin −0.6 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +35.0% vs revenue +14.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 112% of CBRE Group, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.6 B of operating cash against $1.3 B of profit. After $0.8 B of capital spending, $0.8 B was left as free cash.
FY25: operating cash of $1.6 B against reported profit of $1.3 B, leaving free cash of $0.8 B after $0.8 B of capital spending. Across the last 3 fiscal years the conversion rate is 112% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
CBRE Group, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 1.6% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
CBRE Group, Inc. earns a ROE of 13% in FY25. That is up from a trough of 11% in FY24. Return on invested capital clears the cost of that capital by −3.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 3.2% net margin on 1.31× asset turns.
FY25 ROE is 13%, recovered from a FY24 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): 3.2% net margin × 1.31× asset turns × 3.21× balance-sheet leverage ≈ 13.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 5.2% − 8.8% = a −3.6 pp spread. The 8.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
CBRE Group, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
CBRE Group, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
CBRE Group, Inc. carries total debt of $10.6 B against shareholder equity of $9.2 B as of Jun 26, a debt-to-equity of 1.15. On the annual view that ratio went from 0.45 in FY21 to 1.04 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $10.6 B against shareholder equity of $9.2 B — a debt-to-equity of 1.15. On the annual view, debt-to-equity went from 0.45 (FY21) to 1.04 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.7% of CBRE Group, Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 3.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.7% of the float is sold short, and at typical trading volumes it would take about 3.5 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
CBRE Group, Inc.: the Z-score reads 3.32. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.32 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.32.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Jones Lang LaSalle IncorporatedJLL | 62.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.5/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 14.8/25 ROCE 2.8% · OPM 3.2% 76% evidence | 10.9/20 P/E 14.9× · PEG — 15% evidence | 14.8/20 RS sector 9.8% · RS bench -1.6% · 1Y 6.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 14.8 + 10.9 + 14.8 = 62 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2The RMR Group Inc.RMR | 61.0/100Mixed-positive evidence75% evidence | ASLEEP | 15.7/35 Revenue -20.4% · PAT 0% · OPM change 0.3 pp 83% evidence | 14.4/25 ROCE 1.2% · OPM 4.8% 76% evidence | 16.2/20 P/E 12.8× · PEG 0.46 65% evidence | 14.7/20 RS sector 12.5% · RS bench 1.6% · 1Y 14.2%4 of 12 weeks ahead 70% evidence |
| Exact sum: 15.7 + 14.4 + 16.2 + 14.7 = 61 · Decision use: Price leads the evidence: RS versus the benchmark is 1.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 3CBRE Group, Inc.this pageCBRE | 58.3/100Mixed-positive evidence85% evidence | FADING | 22.9/35 Revenue 14.8% · PAT 21.9% · OPM change -0.5 pp 95% evidence | 15.1/25 ROCE 2% · OPM 3.3% 76% evidence | 10.1/20 P/E 30.9× · PEG 1.4 65% evidence | 10.2/20 RS sector -2.2% · RS bench -12.8% · 1Y -15.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 15.1 + 10.1 + 10.2 = 58.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Star HoldingsSTHO | 55.4/100Thin evidence · provisional58% evidence | FADING | 21.2/35 Revenue 11.5% · PAT — · OPM change 21.4 pp 62% evidence | 7.1/25 ROCE -1.2% · OPM -29.6% 76% evidence | 11.5/20 P/E 2.3× · PEG — 15% evidence | 15.6/20 RS sector 14.5% · RS bench 3.1% · 1Y 12.2%8 of 12 weeks ahead 70% evidence |
| Exact sum: 21.2 + 7.1 + 11.5 + 15.6 = 55.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Marcus & Millichap, Inc.MMI | 54.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 22.2/35 Revenue 9.7% · PAT — · OPM change 8.8 pp 62% evidence | 8.4/25 ROCE -0.8% · OPM -3.4% 76% evidence | 9.4/20 P/E 47.7× · PEG — 15% evidence | 14.8/20 RS sector 12.9% · RS bench 1.4% · 1Y -1.5%8 of 12 weeks ahead 70% evidence |
| Exact sum: 22.2 + 8.4 + 9.4 + 14.8 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6FirstService CorporationFSV | 53.0/100Thin evidence · provisional58% evidence | ASLEEP | 20.2/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 15.8/25 ROCE 2.9% · OPM 3.5% 76% evidence | 9.7/20 P/E 40.3× · PEG — 15% evidence | 7.3/20 RS sector -7.6% · RS bench -17.7% · 1Y -34.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 15.8 + 9.7 + 7.3 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7IHS Holding LimitedIHS | 52.9/100Mixed-positive evidence64% evidence | TURNING | 12.1/35 Revenue 3.7% · PAT — · OPM change -15.5 pp 62% evidence | 15.2/25 ROCE 3.2% · OPM 26.8% 76% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 14.8/20 RS sector 12% · RS bench 1% · 1Y 23.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.1 + 15.2 + 10.8 + 14.8 = 52.9 · Decision use: Price leads the evidence: RS versus the benchmark is 1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 8CoStar Group, Inc.CSGP | 50.8/100Thin evidence · provisional58% evidence | BASING | 22.9/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 12.3/25 ROCE 0.8% · OPM 0.3% 76% evidence | 9.3/20 P/E 149.1× · PEG — 15% evidence | 6.3/20 RS sector -33.3% · RS bench -41.7% · 1Y -65.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 12.3 + 9.3 + 6.3 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Newmark Group, Inc.NMRK | 50.8/100Thin evidence · provisional58% evidence | ASLEEP | 20.6/35 Revenue — · PAT — · OPM change 5.8 pp 45% evidence | 13.3/25 ROCE 1.3% · OPM 3.2% 76% evidence | 10.5/20 P/E 18.7× · PEG — 15% evidence | 6.4/20 RS sector -7.3% · RS bench -17.4% · 1Y -26.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 13.3 + 10.5 + 6.4 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Colliers International Group Inc.CIGI | 47.5/100Thin evidence · provisional58% evidence | ASLEEP | 17.5/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence | 14.1/25 ROCE 1.8% · OPM 2.7% 76% evidence | 9.6/20 P/E 44.6× · PEG — 15% evidence | 6.3/20 RS sector -22% · RS bench -31.1% · 1Y -45.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 14.1 + 9.6 + 6.3 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Transcontinental Realty Investors, Inc.TCI | 46.5/100Mixed-negative evidence75% evidence | TURNING | 14.2/35 Revenue 2.1% · PAT 0% · OPM change -10.6 pp 83% evidence | 9.8/25 ROCE -0.2% · OPM -15.9% 76% evidence | 14.0/20 P/E 32× · PEG 0.54 65% evidence | 8.5/20 RS sector -2.2% · RS bench -13.1% · 1Y -13.6%4 of 12 weeks ahead 70% evidence |
| Exact sum: 14.2 + 9.8 + 14 + 8.5 = 46.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Cushman & Wakefield LimitedCWK | 45.9/100Mixed-negative evidence71% evidence | ASLEEP | 18.0/35 Revenue 10.4% · PAT -53.8% · OPM change 0.3 pp 83% evidence | 11.8/25 ROCE 1.1% · OPM 2.3% 76% evidence | 9.9/20 P/E 38.3× · PEG — 15% evidence | 6.2/20 RS sector -8.5% · RS bench -18.5% · 1Y -24.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.8 + 9.9 + 6.2 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13American Realty Investors, Inc.ARL | 45.8/100Thin evidence · provisional58% evidence | ASLEEP | 14.9/35 Revenue 4.2% · PAT — · OPM change -11 pp 62% evidence | 9.1/25 ROCE -0.2% · OPM -17.8% 76% evidence | 10.3/20 P/E 20.3× · PEG — 15% evidence | 11.5/20 RS sector 4.5% · RS bench -6.5% · 1Y -3.3%7 of 12 weeks ahead 70% evidence |
| Exact sum: 14.9 + 9.1 + 10.3 + 11.5 = 45.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14The Real Brokerage Inc.REAX | 43.7/100Thin evidence · provisional55% evidence | BREAKING OUT | 24.0/35 Revenue 46.8% · PAT — · OPM change 0.8 pp 62% evidence | 5.2/25 ROCE -7% · OPM -0.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.5/20 RS sector -28.5% · RS bench -37.3% · 1Y -61.2%6 of 12 weeks ahead 70% evidence |
| Exact sum: 24 + 5.2 + 10 + 4.5 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15RE/MAX Holdings, Inc.RMAX | 43.3/100Mixed-negative evidence74% evidence | 9.2/35 Revenue -5% · PAT -90% · OPM change -18.3 pp 62% evidence | 7.5/25 ROCE -1.8% · OPM -11.1% 76% evidence | 6.6/20 P/E 576× · PEG 1.66 65% evidence | 20.0/20 RS sector 42.8% · RS bench 31.2% · 1Y 31.2%7 of 9 weeks ahead 100% evidence | |
| Exact sum: 9.2 + 7.5 + 6.6 + 20 = 43.3 · Decision use: Price leads the evidence: RS versus the benchmark is 31.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Compass, Inc.COMP | 40.2/100Mixed-negative evidence64% evidence | FADING | 14.9/35 Revenue 40.1% · PAT — · OPM change -9 pp 62% evidence | 4.2/25 ROCE -8.9% · OPM -13% 76% evidence | 9.0/20 P/E 365.5× · PEG — 15% evidence | 12.1/20 RS sector 10.3% · RS bench -1.2% · 1Y 9.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 4.2 + 9 + 12.1 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Seaport Entertainment Group Inc.SEG | 39.1/100Thin evidence · provisional55% evidence | ASLEEP | 12.1/35 Revenue 13.4% · PAT — · OPM change -130.3 pp 62% evidence | 3.8/25 ROCE -7% · OPM -333.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.2/20 RS sector 10.3% · RS bench -0.6% · 1Y 1.9%8 of 12 weeks ahead 70% evidence |
| Exact sum: 12.1 + 3.8 + 10 + 13.2 = 39.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18FRP Holdings, Inc.FRPH | 38.4/100Mixed-negative evidence65% evidence | ASLEEP | 11.4/35 Revenue 4.8% · PAT -85.7% · OPM change -17.8 pp 83% evidence | 11.1/25 ROCE 0.1% · OPM 4.8% 76% evidence | 8.7/20 P/E 547× · PEG — 15% evidence | 7.2/20 RS sector -4.4% · RS bench -14.4% · 1Y -13.5%0 of 12 weeks ahead 70% evidence |
| Exact sum: 11.4 + 11.1 + 8.7 + 7.2 = 38.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19AGNT, IncAGNT | 38.3/100Thin evidence · provisional58% evidence | ASLEEP | 18.6/35 Revenue 5.3% · PAT — · OPM change 0.2 pp 62% evidence | 7.5/25 ROCE -3.8% · OPM -0.9% 76% evidence | 8.8/20 P/E 406× · PEG — 15% evidence | 3.4/20 RS sector -43% · RS bench -50.2% · 1Y -64.7%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.6 + 7.5 + 8.8 + 3.4 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Maui Land & Pineapple Company, Inc.MLP | 35.2/100Mixed-negative evidence65% evidence | ASLEEP | 11.4/35 Revenue 20% · PAT -500% · OPM change -28.5 pp 83% evidence | 4.9/25 ROCE -5.5% · OPM -59.2% 76% evidence | 9.1/20 P/E 239.2× · PEG — 15% evidence | 9.8/20 RS sector 0.5% · RS bench -10% · 1Y -16.5%3 of 12 weeks ahead 70% evidence |
| Exact sum: 11.4 + 4.9 + 9.1 + 9.8 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Douglas Elliman Inc.DOUG | 32.3/100Thin evidence · provisional58% evidence | ASLEEP | 9.7/35 Revenue -5.3% · PAT — · OPM change -6.1 pp 62% evidence | 6.3/25 ROCE -4.8% · OPM -8.2% 76% evidence | 11.1/20 P/E 13.9× · PEG — 15% evidence | 5.2/20 RS sector -17.8% · RS bench -27.3% · 1Y -43.4%2 of 12 weeks ahead 70% evidence |
| Exact sum: 9.7 + 6.3 + 11.1 + 5.2 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Seritage Growth PropertiesSRG | 30.6/100Thin evidence · provisional51% evidence | ASLEEP | 9.2/35 Revenue 0% · PAT — · OPM change -635.5 pp 62% evidence | 7.3/25 ROCE -4.2% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -29.8% · RS bench -38% · 1Y -51.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.2 + 7.3 + 10 + 4.1 = 30.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Opendoor Technologies Inc.OPEN | 21.9/100Adverse evidence61% evidence | ASLEEP | 7.9/35 Revenue -23.2% · PAT — · OPM change -17.2 pp 62% evidence | 4.0/25 ROCE -7.5% · OPM -22.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.0/20 RS sector -49.4% · RS bench -55.4% · 1Y -72.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 4 + 10 + 0 = 21.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Comstock Holding Companies, Inc.CHCI | 66.6/100Thin evidence · provisional47% evidence | BREAKING OUT | 22.3/35 Revenue 24.1% · PAT 13.3% · OPM change — 45% evidence | 13.6/25 ROCE — · OPM — 15% evidence | 14.1/20 P/E 11.4× · PEG 0.83 65% evidence | 16.6/20 RS sector 40.1% · RS bench 26.6% · 1Y 24.4%5 of 12 weeks ahead 70% evidence |
| Exact sum: 22.3 + 13.6 + 14.1 + 16.6 = 66.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Rafael Holdings, Inc.RFL | 54.1/100Thin evidence · provisional24% evidence | 16.3/35 Revenue — · PAT — · OPM change — 8% evidence | 10.9/25 ROCE — · OPM — 15% evidence | 10.6/20 P/E 18.1× · PEG — 15% evidence | 16.3/20 RS sector 32% · RS bench 20.6% · 1Y 23.5%6 of 6 weeks ahead to 2026-08-07 70% evidence | |
| Exact sum: 16.3 + 10.9 + 10.6 + 16.3 = 54.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26New England Realty Associates Limited PartnershipNEN | 43.6/100Thin evidence · provisional48% evidence | BASING | 11.7/35 Revenue 14.8% · PAT -112.5% · OPM change -23.9 pp 83% evidence | 11.9/25 ROCE 0.4% · OPM 6.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y -26.1%0 of 11 weeks ahead 0% evidence |
| Exact sum: 11.7 + 11.9 + 10 + 10 = 43.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Hotel101 Global Holdings Corp.HBNB | 42.7/100Thin evidence · provisional29% evidence | ASLEEP | 18.3/35 Revenue — · PAT — · OPM change — 9% evidence | 8.9/25 ROCE -1.7% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.5/20 RS sector -14.9% · RS bench -24% · 1Y 71.6%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.3 + 8.9 + 10 + 5.5 = 42.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is CBRE Group, Inc.'s stock price today?
CBRE Group, Inc. trades at $139, −15.6% over the past year. The company is valued at $40.0 B. The stock sits at 29% of its 52-week range of $125–$172, −5.5% versus its 200-day average. On the tape, the price is in a downtrend, 2 weeks in. — as of 17 September 2026.
What were CBRE Group, Inc.'s latest quarterly results?
CBRE Group, Inc. reported revenue of $11.2 B and net profit of $0.3 B for the Jun 26 quarter. Revenue rose 15.5% and profit rose 4.2% year on year. Earnings per share were $0.69. The operating margin was 3.2%, 0.6 pp lower than a year earlier. — as of 17 September 2026.
What is CBRE Group, Inc.'s revenue?
CBRE Group, Inc. reported revenue of $11.2 B in the Jun 26 quarter, +15.5% year on year. For the full FY25 fiscal year, revenue was $40.5 B (+13.4%). Over the last 4 years revenue compounded at 9.9% a year. — as of 17 September 2026.
What is CBRE Group, Inc.'s profit?
CBRE Group, Inc. earned $0.3 B of net profit in the Jun 26 quarter, +4.2% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $1.3 B. The operating margin ran 3.2% in the latest quarter. — as of 17 September 2026.
What is CBRE Group, Inc.'s market cap?
CBRE Group, Inc.'s market capitalisation is $40.0 B at a stock price of $139. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is CBRE Group, Inc.'s P/E ratio?
CBRE Group, Inc. trades at a P/E of 32.0×, at the 48th percentile of its own 5-year range, against a long-run median of 32.3×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does CBRE Group, Inc. pay a dividend?
No — CBRE Group, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is CBRE Group, Inc. overvalued?
On its own history, CBRE Group, Inc. looks mid-range: its P/E of 32.0× sits at the 48th percentile of its 5-year range (long-run median 32.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is CBRE Group, Inc. growing?
Yes — CBRE Group, Inc. is growing: latest-quarter revenue +15.5% year on year, profit +4.2%, and the margin −0.6 pp at 3.2%. The 4-year compound rates are 9.9% (revenue) and −8.7% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is CBRE Group, Inc. performing?
CBRE Group, Inc. is in a downtrend, 2 weeks in. Its latest quarter's revenue rose 15.5% and profit rose 4.2% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is CBRE Group, Inc. in?
Mixed — no clean majority across the growth curves, ROCE holding at 10.9% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +14.7% latest, profit growth +23.1% latest, eps growth +22.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is CBRE Group, Inc. in an uptrend?
No — the price is in a downtrend (week 2 of stage 4), trading −5.5% versus its 200-day average and at 29% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is CBRE Group, Inc. beating the market?
On recent form, yes — CBRE Group, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +429% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.
Will CBRE Group, Inc.'s stock price go up?
This page publishes no price forecast for CBRE Group, Inc. What it measures instead: the stock price is $139, the price is in a downtrend 2 weeks in. Its P/E of 32.0× sits at the 48th percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against CBRE Group, Inc.?
No — short interest is 1.7% of CBRE Group, Inc.'s tradable float, about 3.5 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does CBRE Group, Inc. have too much debt?
It carries real leverage — CBRE Group, Inc.'s debt-to-equity is 1.18. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is CBRE Group, Inc.'s capex?
CBRE Group, Inc. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.8 B. — as of 17 September 2026.
What is CBRE Group, Inc.'s cash flow?
CBRE Group, Inc. generated $1.6 B of operating cash flow in FY25 and $0.8 B of free cash flow after $0.8 B of capital spending. Reported profit that year was $1.3 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is CBRE Group, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 112% of CBRE Group, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $1.6 B against reported profit of $1.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is CBRE Group, Inc.?
On the balance sheet, the Z-score reads 3.32 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is CBRE Group, Inc. in its business cycle?
CBRE Group, Inc.'s FY25 operating margin was 4.3%, against a 5-year band of 3.5%–5.9%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 3.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the CBRE Group, Inc. story?
The sharpest disagreement: annual EPS moved +22.6% against a −15.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is CBRE Group, Inc. a stock worth studying right now?
This is not investment advice. The machine read: CBRE Group, Inc.'s earnings have outrun its stock. EPS grew +22.6% in a year against a −15.6% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!